Abstract:Inactivation of all herpes simplex virus (HSV) immediate early (IE) genes to eliminate vector cytotoxicity results in rapid silencing of the viral genome, similar to the establishment of HSV latency. We recently reported that silencing of a nonviral reporter cassette could be overcome in nonneuronal cells by positioning the cassette in the viral latency (LAT) locus between resident chromatin boundary elements. Here, we tested the abilities of the chicken hypersensitive site 4 insulator and the human ubiquitous chromatin opening element A2UCOE to promote transgene expression from an IE-gene-inactivated HSV vector. We found that A2UCOE was particularly active in nonneuronal cells and reduced reporter promoter occupancy by a repressive histone mark. We determined whether multiple transgenes could be expressed under the control of different promoters from different loci of the same virus. The results showed abundant coexpression of LAT-embedded and A2UCOE-flanked genes in nonneuronal cells. In addition, a third reporter gene without known protective elements was active in cultured rat sensory neurons. These findings indicate that cellular antisilencing sequences can contribute to the expression of multiple genes from separate promoters in fully IE gene-disabled HSV vectors, providing an opportunity for therapeutic applications requiring mutually independent expression of different gene products from a single vector. IMPORTANCE Gene therapy has now entered a phase of development in which a growing number of recessive single gene defects can be successfully treated by vector-mediated introduction of a wild-type copy of the gene into the appropriate tissue. However, many disease conditions, such as neurodegeneration, cancer, and inflammatory processes, are more complex, requiring either multiple gene corrections or provision of coordinated gene activities to achieve a therapeutic outcome. Although herpes simplex virus (HSV) vectors have the capacity to meet this need, the challenge has been to genetically engineer the HSV genome in a manner to prevent expression of any viral genes while retaining the ability to express multiple therapeutic transgenes under independent transcriptional control. Here, we show that non-HSV insulator elements can be applied to retain at least transient transgene activity from multiple viral loci, thereby opening the door for more complex gene therapy applications in the future.

An Improved Tet-on System for Gene Expression in Neurons Delivered by a Single Lentiviral Vector.

Construction and Identification of Lentiviral Vector-mediated RNA Interference of Epidermal Growth Factor Receptor

Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors

Construction of novel conditional transgenic vectors for molecular therapy based on the Tet-On system and flanked with insulators in a single plasmid

A More Efficient RNAi Inducible System for Tight Regulation of Gene Expression in Mammalian Cells and Xenograft Animals.

Lentiviral vectors with two independent internal promoters transfer high-level expression of multiple transgenes to human hematopoietic stem-progenitor cells.

Inducible and Reversible Transgene Expression in Human Stem Cells after Efficient and Stable Gene Transfer

Transactivator and Structurally Optimized Inducible Lentiviral Vectors.

Tetracycline-、controlled LacZ Gene Expression in Primary Cultured Neurons Mediated by a Tetracycline Regulated Replication-Defective HSV-1 Vector System

Improved gene expression by a modified bicistronic retroviral vector.

Efficient Tet-dependent expression of human factor IX in vivo by a new self-regulating lentiviral vector

A New Approach with Less Damage: Intranasal Delivery of Tetracycline-Inducible Replication-Defective Herpes Simplex Virus Type-1 Vector to Brain

Improved transduction efficiency of a lentiviral vector for neuron-specific retrograde gene transfer by optimizing the junction of fusion envelope glycoprotein

Cellular Antisilencing Elements Support Transgene Expression from Herpes Simplex Virus Vectors in the Absence of Immediate Early Gene Expression

Tetracycline controlled DT/VEGF system gene therapy mediated by adenovirus vector

Enhanced lentiviral gene delivery to mammalian cells via paired cell surface and viral envelope engineering

A Self-Deletion Lentiviral Vector to Reduce the Risk of Replication-Competent Virus Formation

Gene delivery into primary cerebral cortical neurons by lentiviral vector.

653. the Controlled Transgene Expression in Oncolytic Adenoviral Vectors with Major Late Promoter for Therapy of Cancer

Deletion of the Virion Host Shut-off Gene Enhances Neuronal-Selective Transgene Expression from an HSV Vector Lacking Functional IE Genes

Lentiviral Delivery of Proteins for Genome Engineering